138483-63-3
138483-63-3 structure
- Name: L-689502
- Chemical Name: tert-butyl N-[(2S,3S,5R)-3-hydroxy-6-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-[[4-(2-morpholin-4-ylethoxy)phenyl]methyl]-6-oxo-1-phenylhexan-2-yl]carbamate
- CAS Number: 138483-63-3
- Molecular Formula: C39H51N3O7
- Molecular Weight: 673.83800
- Catalog: Signaling Pathways Metabolic Enzyme/Protease HIV Protease
- Create Date: 2017-04-09 06:11:23
- Modify Date: 2025-08-19 19:34:44
-
L-689502 is a potent inhibitor of HIV-l protease with an IC50 of 1 nM.
| Name | tert-butyl N-[(2S,3S,5R)-3-hydroxy-6-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-[[4-(2-morpholin-4-ylethoxy)phenyl]methyl]-6-oxo-1-phenylhexan-2-yl]carbamate |
|---|---|
| Synonyms |
Des-3-pyridylmethyl Indinavir
(2S)-1-[(2S,4S)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butylpiperazine-2-carboxamide [14C]-N-Dealkyl Indinavir N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(2(S)-N-(tert-butylcarboxamido)piperazinyl))pentanamide N-(2(R)-hydroxy-1(S)-indanyl)-5(S)-[(tert-butyloxycarbonyl)amino]-4(S)-hydroxy-6-phenyl-2(R)-({4-[2-(4-morpholinyl)ethoxy]phenyl}methyl)hexanamide (1S,2R,2'R,4'S,2"S)-1-((2-benzyl-5-(((2-(t-butyl)amino)carbonyl)piperazin-1-yl)-4-hydroxypentanoyl)amino)indan-2-ol indinavir penultimate 2,3,5-Trideoxy-N-[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]-5-[(2S)-2-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperazinyl]-2-(phenylmethyl)-D-erythro-pentonamide N-(2(R)-hydroxy-1(S)-indanyl)-5(S)-(1,1-dimethylethoxycarbonyl)amino-4(S)-hydroxy-6-phenyl-2(R)-(4-(2-(4-morpholinyl)ethoxy)phenyl)methyl hexanamide L-689502 |
| Description | L-689502 is a potent inhibitor of HIV-l protease with an IC50 of 1 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1 nM (HIV-l protease)[1] |
| In Vitro | Both L694746 and L-689502 inhibit HIV-l ptotease activity in a concentration-dependent manner. Pepstatin is much less potent than either compound exhibiting an IC50 of 2 μM. L694746 is as potent as L-689502 in inhibiting the HIV-l protease despite being structurally different from L-689502[1]. |
| Cell Assay | G689502 (3.3 pmoles in 1 mL of 100% DMSO) is added to cultures that have been growing for 48 hr. The final substrate and DMSO concentrations during the fermentation period are 65 pM and 2%, respectively. The fermentations containing L-689502 are carried out for an additional 72-96 hr prior to be harvested.The whole broth is sequenthdly extracted with methanol (0.5 vol) and acetone (0.5 vol). The supematant containing the derivatives of L-689502 is separated from the mycelia by filtration[1]. |
| References |
| Density | 1.24g/cm3 |
|---|---|
| Boiling Point | 886.9ºC at 760 mmHg |
| Molecular Formula | C39H51N3O7 |
| Molecular Weight | 673.83800 |
| Flash Point | 490.2ºC |
| Exact Mass | 673.37300 |
| PSA | 136.57000 |
| LogP | 5.20040 |
| Vapour Pressure | 9.83E-34mmHg at 25°C |
| Index of Refraction | 1.615 |
| Storage condition | 2-8℃ |
|
~99%
138483-63-3 |
| Literature: Thompson; Fitzgerald; Holloway; Emini; Darke; McKeever; Schleif; Quintero; Zugay; Tucker; Schwering; Homnick; Nunberg; Springer; Huff Journal of Medicinal Chemistry, 1992 , vol. 35, # 10 p. 1685 - 1701 |
|
~%
138483-63-3 |
| Literature: Thompson; Fitzgerald; Holloway; Emini; Darke; McKeever; Schleif; Quintero; Zugay; Tucker; Schwering; Homnick; Nunberg; Springer; Huff Journal of Medicinal Chemistry, 1992 , vol. 35, # 10 p. 1685 - 1701 |
|
~%
138483-63-3 |
| Literature: Thompson; Fitzgerald; Holloway; Emini; Darke; McKeever; Schleif; Quintero; Zugay; Tucker; Schwering; Homnick; Nunberg; Springer; Huff Journal of Medicinal Chemistry, 1992 , vol. 35, # 10 p. 1685 - 1701 |
|
~%
138483-63-3 |
| Literature: Thompson; Fitzgerald; Holloway; Emini; Darke; McKeever; Schleif; Quintero; Zugay; Tucker; Schwering; Homnick; Nunberg; Springer; Huff Journal of Medicinal Chemistry, 1992 , vol. 35, # 10 p. 1685 - 1701 |
|
~%
138483-63-3 |
| Literature: Thompson; Fitzgerald; Holloway; Emini; Darke; McKeever; Schleif; Quintero; Zugay; Tucker; Schwering; Homnick; Nunberg; Springer; Huff Journal of Medicinal Chemistry, 1992 , vol. 35, # 10 p. 1685 - 1701 |
|
~%
138483-63-3 |
| Literature: Thompson; Fitzgerald; Holloway; Emini; Darke; McKeever; Schleif; Quintero; Zugay; Tucker; Schwering; Homnick; Nunberg; Springer; Huff Journal of Medicinal Chemistry, 1992 , vol. 35, # 10 p. 1685 - 1701 |
|
~%
138483-63-3 |
| Literature: Askin, D.; Wallace, M. A.; Vacca, J. P.; Reamer, R. A.; Volante, R. P.; Shinkai, I. Journal of Organic Chemistry, 1992 , vol. 57, # 10 p. 2771 - 2773 |
|
~%
138483-63-3 |
| Literature: Askin, D.; Wallace, M. A.; Vacca, J. P.; Reamer, R. A.; Volante, R. P.; Shinkai, I. Journal of Organic Chemistry, 1992 , vol. 57, # 10 p. 2771 - 2773 |
|
~%
138483-63-3 |
| Literature: Askin, D.; Wallace, M. A.; Vacca, J. P.; Reamer, R. A.; Volante, R. P.; Shinkai, I. Journal of Organic Chemistry, 1992 , vol. 57, # 10 p. 2771 - 2773 |
| Precursor 3 | |
|---|---|
| DownStream 0 | |